☆ 4.4 Letter

Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial

ACTA ONCOLOGICA (2022)

Related references

Note: Only part of the references are listed.

Article Economics

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

Don Husereau et al.

Summary: The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. The new CHEERS 2022 statement replaces previous guidance and reflects the need for guidance that can be applied to all types of health economic evaluation and includes stakeholder involvement.

VALUE IN HEALTH (2022)

Add to Collection

Review Oncology

A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing

Sarah Glewis et al.

Summary: Pharmacogenetics Guided Dosing (PGD) improves treatment outcomes by reducing the incidence of toxicities, particularly overall toxicity and diarrhea, without impacting treatment response in patients receiving 5-fluorouracil/capecitabine therapy.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Editorial Material Medicine, General & Internal

Teletrials: implementation of a new paradigm for clinical trials

Ian M. Collins et al.

MEDICAL JOURNAL OF AUSTRALIA (2020)

Add to Collection

Article Oncology

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype

David Paez et al.

BRITISH JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis

Linda M. Henricks et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Review Pharmacology & Pharmacy

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Femke M. de Man et al.

CLINICAL PHARMACOKINETICS (2018)

Add to Collection

Article Oncology

Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

Carin A. T. C. Lunenburg et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Oncology

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

Didier Meulendijks et al.

LANCET ONCOLOGY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.